Concepedia

Author

Sebastian Grosicki

Medical University of SilesiaORCID

Also Known As

Grosicki, Sebastian, Grosicki, Sebastian; Oddział Hematologiczny SPZOZ, Zespół Szpitali Miejskich, ul. Karola Miarki 40, 41–500 Chorzów, Poland, Grosicki,Sebastian, S Grosicki, S. Grosicki, Sebastian Grosicki

422

Publications

16.1K

Citations

48

H-Index

63

Concepts

All Affiliations

Medical University of SilesiaNational and Kapodistrian University of AthensMedical University of LodzDana-Farber Cancer InstituteMedical University of Lublin
SG

About

Sebastian Grosicki is an author at Medical University of Silesia specializing in medicine, oncology, and hematology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

30

59

7.1K

2

Health Sciences

24

40

4.1K

3

Cellular Therapies

4

4

303

4

Allergy

1

1

12

5

Geriatrics

1

1

23

Sebastian Grosicki

×

134

Publications

15.1K

Citations

47

H-Index

YearCitations

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

Jan A. Burger, Alessandra Tedeschi, Paul M. Barr,

New England Journal of Medicine

2015

1.5K

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

Sagar Lonial, Meletios Α. Dimopoulos, Antonio Palumbo,

New England Journal of Medicine

2015

1.3K

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

María‐Victoria Mateos, Meletios Α. Dimopoulos, Michèle Cavo,

New England Journal of Medicine

2017

949

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

Philippe Moreau, Halyna Pylypenko, Sebastian Grosicki,

The Lancet Oncology

2011

910

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

Michel Attal, Paul G. Richardson, S. Vincent Rajkumar,

The Lancet

2019

620

Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma

Meletios Α. Dimopoulos, Dominik Dytfeld, Sebastian Grosicki,

New England Journal of Medicine

2018

526

Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study

Jan A. Burger, Paul M. Barr, Tadeusz Robak,

Leukemia

2019

447

Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial

María‐Victoria Mateos, Michèle Cavo, Joan Bladé,

The Lancet

2019

430

Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

Jennifer R. Brown, Barbara Eichhorst, Peter Hillmen,

New England Journal of Medicine

2022

414

Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study

Asher Chanan‐Khan, Paula Cramer, Fatih Demırkan,

The Lancet Oncology

2015

408

Page 1